Year archive

Orexo — 2015 filings

All 65 regulatory filings released by Orexo (ORX) in 2015, sourced directly from the official regulator.

65 Filings

2015 Period

2015 filings (65)

Filing	Released	Lang
Orexo receives MGBP 5 milestone payment for Abstral® in Europe and records OX-MPI non-cash impairment charge of MSEK 62 Earnings Release Q4 2015	2015-12-11	English
Orexo erhåller 5 MGBP som delmålsersättning för Abstral® i Europa och redovisar en ej kassaflödespåverkande nedskrivning av OX-MPI om 62 MSEK Earnings Release Q4 2015	2015-12-11	Swedish
New Abstral® partner in the US Regulatory Filings	2015-11-20	English
Ny samarbetspartner gällande Abstral® i USA M&A Activity	2015-11-20	Swedish
Orexo förlikas med Actavis om patentintrång avseende Abstral® i USA Legal Proceedings Report	2015-10-27	Swedish
Orexo Settles Abstral® US Patent Litigation with Actavis Legal Proceedings Report	2015-10-27	English
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-10-22	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report 9M 2015	2015-10-22	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-10-16	English
Orexo appoints Nomination Committee and publishes financial calendar 2015/2016 Board/Management Information	2015-10-15	English
Orexo utser valberedning och offentliggör finansiell kalender 2015/2016 AGM Information	2015-10-15	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-10-01	English
New regulations will expand access to treatment of opioid dependence in the US Regulatory Filings	2015-09-18	English
Nya regler kommer att öka tillgången till behandling av opiatberoende i USA Regulatory Filings	2015-09-18	Swedish
Letter to Orexo shareholders from CEO Nikolaj Sørensen Management Reports	2015-09-02	English
Brev till aktieägare i Orexo från VD Nikolaj Sørensen Report Publication Announcement	2015-09-02	Swedish
Orexo’s Upcoming Presentations at Events during Second Half 2015 Regulatory Filings	2015-08-25	English
Orexos kommande presentationer på evenemang under andra halvåret 2015 Report Publication Announcement	2015-08-25	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-08-20	English
Declaration of Voting Results & Voting Rights Announcements 2015 Declaration of Voting Results & Voting Rights Announcements	2015-08-19	English
U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence Regulatory Filings	2015-08-11	English
Amerikanska FDA godkänner Zubsolv® för initiering av underhållsbehandling med buprenorfin för patienter som lider av opiatberoende Earnings Release FY 2015	2015-08-11	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-08-06	English
ZUBSOLV® Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid Regulatory Filings	2015-08-04	English
Zubsolv® uppdatering om avtal med CVS Caremark och information om nytt exklusivt avtal inom Managed Medicaid Regulatory Filings	2015-08-04	Swedish
Antal aktier och röster i Orexo Declaration of Voting Results & Voting Rights Announcements	2015-07-31	Swedish
Number of shares and votes in Orexo Transaction in Own Shares	2015-07-31	English
Earnings Release 2015 Earnings Release H1 2015	2015-07-10	Swedish
Earnings Release 2015 Earnings Release H1 2015	2015-07-10	English
Antal aktier och röster i Orexo Share Issue/Capital Change	2015-06-30	Swedish
Number of shares and votes in Orexo Share Issue/Capital Change	2015-06-30	English
Orexo’s “Out the Monster” campaign wins a Gold Lions Health Award at the Cannes Lions Festival Regulatory Filings	2015-06-25	English
Orexos kampanj ”Out the Monster” vinner Gold Lions Health Award på Cannes Lions Festival Regulatory Filings	2015-06-25	Swedish
Issue and repurchase of class C shares Transaction in Own Shares	2015-06-17	English
Emission och återköp av C-aktier Share Issue/Capital Change	2015-06-17	Swedish
FDA approves the medium tablet strength, 2.9 mg/0.71 mg, of ZUBSOLV® Regulatory Filings	2015-06-10	English
FDA godkänner en medium tablettstyrka (2,9 mg/0,71 mg) av Zubsolv® Regulatory Filings	2015-06-10	Swedish
Number of shares and votes in Orexo Declaration of Voting Results & Voting Rights Announcements	2015-05-29	English
Antal aktier och röster i Orexo Share Issue/Capital Change	2015-05-29	Swedish
Orexo presenterar på Redeye Investor Forum i Göteborg Regulatory Filings	2015-05-06	Swedish
Orexo divests subsidiary Kibion M&A Activity	2015-04-30	English
Orexo avyttrar dotterbolaget Kibion M&A Activity	2015-04-30	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-04-23	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-04-23	English
Orexo to present at 2015 Nordic Life Sciences Conference Regulatory Filings	2015-04-22	English
Ny 24-veckors klinisk studie stärker bevisen om behandlingsvärdet av Zubsolv® vid underhållsbehandling av opiatberoende Regulatory Filings	2015-04-22	Swedish
Report from Orexo AB’s annual general meeting, 15 April 2015 AGM Information	2015-04-15	English
Kommuniké från Orexo AB:s årsstämma den 15 april 2015 AGM Information	2015-04-15	Swedish
Number of shares and votes in Orexo Declaration of Voting Results & Voting Rights Announcements	2015-03-31	English
Antal aktier och röster i Orexo Declaration of Voting Results & Voting Rights Announcements	2015-03-31	Swedish
Annual Report 2014 Annual Report FY 2014	2015-03-25	Swedish
Annual Report 2014 Annual Report FY 2014	2015-03-25	English
Notice of Annual General Meeting of Orexo AGM Information	2015-03-16	English
Kallelse till årsstämma i Orexo AGM Information	2015-03-16	Swedish
Orexo breddar produktsortimentet för Zubsolv® och meddelar listning av ett nytt godkänt patent i USA Regulatory Filings	2015-02-17	Swedish
Orexo broadens ZUBSOLV® product range and announces newly listed granted US patent. Regulatory Filings	2015-02-17	English
Orexo stämmer Actavis för patentintrång avseende Abstral® i USA Legal Proceedings Report	2015-02-05	Swedish
Orexo commences patent infringement litigation against Actavis concerning Abstral® in the US Legal Proceedings Report	2015-02-05	English
Antal aktier och röster i Orexo Share Issue/Capital Change	2015-01-30	Swedish
Number of shares and votes in Orexo Share Issue/Capital Change	2015-01-30	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-01-29	English
Earnings Release 2014 Earnings Release FY 2014	2015-01-29	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report FY 2014	2015-01-29	English
Orexo Receives Paragraph IV Notice Letter Concerning Abstral® in the US Legal Proceedings Report	2015-01-15	English
Orexo har mottagit Paragraph IV-meddelande rörande Abstral® i USA Legal Proceedings Report	2015-01-15	Swedish

Filings by year

2026 10 filings
2025 26 filings
2024 27 filings
2023 24 filings
2022 16 filings
2021 25 filings
2020 33 filings
2019 30 filings
2018 32 filings
2017 28 filings
2016 45 filings
2015 65 filings
2014 64 filings
2013 75 filings
2012 75 filings
2011 65 filings
2010 60 filings
2009 49 filings
2008 53 filings
2007 41 filings